Author: Dorron Blumberg

TherapeuticsMD Announces FDA Approval of TX-004HR: IMVEXXYTM (estradiol vaginal inserts), the Lowest Dose Vaginal Estrogen Product Approved for the Treatment of Moderate to Severe Dyspareunia, a Symptom of VVA, due to Menopause

BOCA RATON, Fla.-TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that the United States Food and Drug Administration (FDA) has approved IMVEXXYTM (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy (VVA), due to menopause. IMVEXXY is the only product in its therapeutic class to offer a 4 mcg and 10 mcg dose, the 4 mcg representing the lowest approved dose of vaginal estradiol available.

Read More

Catalyst Pharmaceuticals Announces FDA Acceptance of NDA and Priority Review Status for Firdapse® (Amifampridine Phosphate) for Lambert-Eaton Myasthenic Syndrome

CORAL GABLES, Fla., Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, announced today that its New Drug Application (NDA) for Firdapse® for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) has been accepted for a Priority Review by the U.S. Food and Drug Administration (FDA).

Read More

Wireless Bittium BrainStatus™ meant for real-time brain electrical activity monitoring received medical device approval in Europe

Oulu, Finland, May 29, 2018 – Bittium BrainStatus™ is a wireless EEG-monitoring device, meant for real-time brain electrical activity monitoring, has received medical device approval in Europe. The Bittium BrainStatus EEG monitoring device enables high quality and fast EEG signal measurement.

Bittium BrainStatus consists of a wireless compact EEG amplifier and a disposable electrode headband that is quick to wear below the hairline. 

Read More